Active Ingredient: CETUXIMAB
Cetuximab is an anti-EGFR monoclonal antibody used in advanced solid tumors that demonstrates no clinically meaningful effect on cardiac repolarization or QTc intervals. In a dedicated clinical trial evaluating standard dosing (400 mg/m2 loading dose followed by 250 mg/m2 weekly), time-matched serum concentration-to-QTc analyses confirmed an absence of exposure-dependent repolarization delay. Furthermore, cetuximab produced no significant changes in heart rate, PR interval, or QRS duration, indicating it can be safely administered without intrinsic QTc prolongation risk.
https://doi.org/10.1007/s00280-013-2146-5